Eli Lilly obesity pill orforglipron led to 12% weight loss

60-Second Summary

Eli Lilly announced positive late-stage trial results for its oral obesity drug, orforglipron, showing nearly 12% weight loss in patients at the highest dose. While slightly lower than expectations and comparable to Novo Nordisk's Wegovy, doctors praised its potential to reach patients averse to injections. Despite a stock dip, Eli Lilly plans to submit the data to regulators this year for a 2026 launch. The pill could significantly expand access to obesity treatments, addressing current supply constraints and potentially lower costs compared to injectable options.